PDCD1 and cancer: EMB-02 is a symmetric tetravalent IgG-like bispecific antibody against PD-1 and LAG-3 developed by Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, designed to target human PD-1 and LAG-3 concomitantly or independently to disrupt the immune suppression mediated by both pathways, thereby restoring T-cell effector function to enhance anti-cancer immunity.